Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBIT ratio is N/A as of 2026-10-06T15:56:35.319Z.
Calculation as of: 2026-10-06T15:56:35.319Z.
Quote observation: 2026-10-06T15:50:23.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: bcc3f1894ec499320e43c54a24f2662d6ad9e54feca4b92c79248349e67b8166
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBIT RATIO
N/A
Market Cap
$4.10M
EV/EBIT Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$4.43M
EV/EBIT Ratio
N/A
TTM Avg
661.60x
3Y Avg
661.60x
5Y Avg
661.60x
| NAME | MARKET CAP | EV/EBIT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| GRI Bio, Inc. (GRI) | $4.20M | N/A | N/A | N/A | N/A |
| Aptevo Therapeutics Inc. (APVO)vs › | $4.05M | N/A | N/A | N/A | N/A |
| Ernexa Therapeutics Inc. (ERNA)vs › | $4.00M | N/A | N/A | N/A | N/A |
| Processa Pharmaceuticals, Inc. (PCSA)vs › | $4.10M | N/A | N/A | N/A | N/A |
| 20/20 Biolabs Inc. (AIDX)vs › | $4.26M | N/A | N/A | N/A | N/A |
| CollPlant Biotechnologies Ltd. (CLGN)vs › | $4.43M | N/A | 661.60x | 661.60x | 661.60x |
| PharmaCyte Biotech, Inc. (PMCB)vs › | $4.45M | N/A | N/A | N/A | N/A |
| Dermata Therapeutics, Inc. (DRMA)vs › | $4.50M | N/A | N/A | N/A | N/A |
| Nexalin Technology, Inc. (NXL)vs › | $3.51M | N/A | N/A | N/A | N/A |
| Moolec Science S.A. (MLEC)vs › | $3.39M | N/A | N/A | N/A | N/A |
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
